Zenas BioPharma, Inc. (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company focused on autoimmune diseases, and its news flow reflects active development across multiple programs. Company announcements frequently highlight progress with its lead product candidate, obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb across the B cell lineage to inhibit cells implicated in autoimmune disease without depleting them. News items include updates on the Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease (IgG4-RD), Phase 2 MoonStone trial in Relapsing Multiple Sclerosis (RMS), and Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE), including reports of statistically significant efficacy results and safety findings.
Investors following ZBIO news can also track developments related to orelabrutinib, a late-stage, highly selective CNS-penetrant, oral BTK inhibitor licensed from InnoCare Pharma. Press releases cover Phase 3 trials in Primary Progressive Multiple Sclerosis (PPMS) and planned trials in Secondary Progressive Multiple Sclerosis (SPMS), as well as partner-reported data in SLE. Additional news covers earlier-stage programs ZB021 and ZB022, described as potentially best-in-class oral IL-17AA/AF and TYK2 inhibitors in IND-enabling or preclinical stages.
Regulatory, financing and corporate updates are another key component of Zenas BioPharma’s news. The company issues releases on revenue participation and funding agreements, such as its obexelimab funding arrangement with Royalty Pharma, private placement financings, and material license agreements with InnoCare. Earnings-related press releases and Form 8-K–linked announcements provide context on cash runway, research and development spending, and strategic priorities.
This ZBIO news page aggregates these disclosures so readers can follow clinical milestones, regulatory plans, licensing transactions and capital raises associated with Zenas’ autoimmune pipeline. For investors, analysts and healthcare professionals, it offers a single view into how obexelimab, orelabrutinib, ZB021 and ZB022 are progressing through development and how the company is structuring partnerships and funding to support its programs.
Zenas BioPharma (Nasdaq: ZBIO) granted 74,900 restricted stock units to newly hired employees on October 15, 2026, as employment inducements.
The awards, which represent rights to shares of common stock, vest in four equal annual installments: 25% on each of October 15, 2027, 2028, 2029 and 2030. Vesting requires continued service through each applicable date. The Compensation Committee approved the grants under Nasdaq Listing Rule 5635(c)(4), subject to the 2026 Inducement Plan and applicable award agreements.
Zenas BioPharma (Nasdaq: ZBIO) presented new obexelimab findings in IgG4-related disease from the Phase 3 INDIGO trial and its extension. The data were presented at the October 8–10, 2026 international symposium in Cambridge, Massachusetts.
In the open-label extension, where participants knew their treatment, the 12-month probability of remaining flare-free was 0.93 using investigator- and committee-confirmed flares requiring rescue therapy, versus 0.87 using investigator-determined flares requiring rescue therapy; five patients awaited adjudication. At week 52, cumulative steroid toxicity was lower versus placebo, with a score difference of -11.4; p=0.021. Initial vaccine sub-study findings showed blood markers of immunity to influenza in 6 of 7 participants and COVID-19 in 4 of 4 following vaccination during a treatment-free window.
Zenas BioPharma (Nasdaq: ZBIO) will present seven posters at MSToronto2026, the Joint ACTRIMS-ECTRIMS Meeting, on October 21–23, 2026, in Toronto, Canada.
Orelabrutinib presentations cover how the drug is processed in the body in relapsing-remitting multiple sclerosis, designs of the Monarch and PriMroSe Phase 3 trials in progressive multiple sclerosis, and 24-week efficacy and safety results for the 80 mg dose in a Phase 2 study. Obexelimab presentations cover biomarkers and disease activity, 24-week results, and how the drug is processed and acts in the body, all from the Phase 2 MoonStone trial in relapsing multiple sclerosis.
Zenas will also host an expert-panel symposium on BTK inhibition and disability progression in multiple sclerosis on October 21, from 5:30–6:30 p.m. ET. The four paper-poster presentations are scheduled for October 22, from 4:30–6:30 p.m. ET.
Zenas BioPharma (ZBIO) will host a virtual research and development event on October 27, 2026, featuring management presentations on its pipeline. The event runs from 8:00–9:30 a.m. ET and will cover investigational obexelimab, currently being evaluated in systemic lupus erythematosus, and ongoing development of ZB021. Dr. Joseph F. Merola will discuss biology and clinical considerations. A webcast replay will be available afterward.
Zenas BioPharma (ZBIO) will present new Phase 3 INDIGO data on obexelimab in immunoglobulin G4‑related disease (IgG4‑RD) at two scientific meetings in October and November 2026.
Longer‑term flare protection and safety data from the INDIGO open‑label extension will be presented on October 10 at the IgG4ward! 6th International Symposium on IgG4‑Related Disease in Cambridge, Massachusetts. Across this symposium and ACR Convergence 2026 in Orlando, presentations will also cover glucocorticoid‑associated toxicity and influenza/SARS‑CoV‑2 vaccine responses in patients with IgG4‑RD treated with obexelimab, through both oral and poster sessions.
Zenas BioPharma (ZBIO) granted equity awards to new employees on September 15, 2026 under Nasdaq Listing Rule 5635(c)(4).
The awards comprise non-qualified stock options for an aggregate 53,700 common shares and 98,900 restricted stock units as inducements to join the company. The options have a ten-year term with an exercise price of $31.93, equal to the Grant Date closing price. Option vesting occurs over four years, with 25% after one year of employment and the balance in 36 equal monthly installments. RSUs vest in four equal annual installments on September 15 of 2027, 2028, 2029 and 2030, subject to continued service and the terms of the 2026 Inducement Plan and award agreements.
Zenas BioPharma (ZBIO) will host a virtual Obexelimab IgG4-RD investor event on September 29, 2026.
The event will run from 8:00 to 9:30 a.m. ET and feature Zenas management and Guy Katz, M.D., from Massachusetts General Hospital. Presenters will review Immunoglobulin G4-Related Disease, current treatment approaches, unmet needs, and Zenas’ prelaunch preparedness and potential commercial opportunity for obexelimab in IgG4-RD, if approved. The FDA has accepted Zenas’ Biologics License Application for obexelimab for IgG4-RD, assigning a PDUFA target action date of May 27, 2027. Zenas also expects to submit a Marketing Authorization Application to the EMA in the second half of 2026.
Zenas BioPharma (ZBIO) will present at three upcoming healthcare investor conferences in September 2026.
Management is scheduled to speak at the Citi Biopharma Back to School Conference on September 9 at 4:20 p.m. ET, the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 at 4:05 p.m. ET, and the H.C. Wainwright 28th Annual Global Investment Conference on September 16 at 8:00 a.m. ET. Live webcasts and replays will be available on the company’s website under “Events and Presentations.”
Zenas BioPharma (Nasdaq: ZBIO) reported that on August 17, 2026 its Board Compensation Committee granted an aggregate of 11,000 restricted stock units (RSUs) to newly hired employees as employment inducement awards under Nasdaq Listing Rule 5635(c)(4). The RSUs were issued outside the company’s equity incentive plans under a dedicated 2026 Inducement Plan.
The RSUs vest in four equal annual installments, with 25% vesting on each of August 15, 2027, 2028, 2029 and 2030, subject to the employees’ continued service with Zenas through each vesting date. The awards are governed by the 2026 Inducement Plan and the applicable individual award agreements.
Zenas BioPharma (Nasdaq: ZBIO) reported Q2 2026 results and major pipeline progress, led by FDA acceptance of its Biologics License Application for obexelimab in IgG4-related disease, with a PDUFA target action date of May 27, 2027. Positive Phase 3 INDIGO data showed a 56% reduction in flare risk versus placebo and supported global regulatory filings, including an expected EMA Marketing Authorization Application in 2H 2026 and a PMDA submission by partner Bristol Myers Squibb.
Zenas confirmed bioequivalence for a single-dose prefilled obexelimab pen, advanced its ZB021 Phase 1 program, and continued Phase 3 trials of orelabrutinib in multiple sclerosis. The company reported $673.9 million in cash, cash equivalents and investments, Q2 revenue of $1.0 million, and a net loss of $111.5 million, and projects funding runway at least through Q2 2029 under specified milestone and financing assumptions.